Le Lézard
Classified in: Health, Science and technology, Business

Egret Therapeutics Receives FDA Clearance of IND Application for EGT 101 for Treatment of Delayed Cerebral Ischemia

Egret Therapeutics, a portfolio company of Turret Capital Management, announces FDA Clearance of its IND Application for EGT 101

NEW YORK, Feb. 4, 2023 /PRNewswire/ -- Egret Therapeutics, a clinical-stage biotechnology company focused on developing transformative therapies for neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for EGT 101 that is being studied for the treatment of Delayed Cerebral Ischemia (DCI) following aneurysmal subarachnoid hemorrhage. The Phase I/II trial is expected to begin enrolling patients in 2023.

"We are thrilled to have received IND clearance for our program in aneurysmal subarachnoid hemorrhage," said Daniel Chai, M.D., Co-Founder and Chief Executive Officer of Egret Therapeutics. "Clearance of this IND is a testament to the hard work and deep commitment from the Egret team in bringing drugs to the market that will help patients," said Henry Park, Chief Financial Officer of Egret Therapeutics.

Among subarachnoid hemorrhage (SAH) patients who survive the initial bleed of a ruptured aneurysm, delayed cerebral ischemia (DCI) is the most important preventable cause of mortality and poor neurological outcome. "DCI prevention has been the focus of SAH research for decades, but few clinical options exist today. We are excited to move forward in our clinical development of EGT 101 with the hopes of bringing a therapy to patients where there is a high unmet need," said Chris Jackson, M.D., Co-Founder and Chief Medical Officer of Egret Therapeutics.

About Egret Therapeutics

Egret Therapeutics is a clinical-stage biotherapeutics company. The company is focused on developing products to address areas of clinical unmet need in neurological diseases. 

For more information, visit us at www.egrettherapeutics.com




SOURCE Turret Capital Management

These press releases may also interest you

at 05:00
Tidewater Midstream and Infrastructure Ltd. ("Tidewater") is pleased to announce that its Board of Directors has declared a dividend for the first quarter 2023 of $0.01 per common share payable on or about April 28, 2023 to shareholders of record on...

at 05:00
About 3 in 5 undergraduates cited personal mental health as a reason they considered stopping their coursework in the last six months, according to a new study by Gallup and Lumina Foundation. The report, Stressed out and Stopping Out: The Mental...

at 05:00
Halfpricesoft.com has an import feature with the new version of ezW2Correction to allow W2 data to be uploaded to W-2c forms, saving time and increasing accuracy. As an added perk, the software prints W-2C (copy 1, 2, A, B, C and D) and...

at 05:00
Hexaware Technologies, a global IT services company, and Xceptor, a leading data automation platform provider, have launched a new Center of Excellence and Solution factory in Pune, India. The partnership combines Hexaware's banking & financial...

at 05:00
FBS has ended its Ultimate Trading Birthday promotion with a raffle of great prizes. Mercedes-Benz CLA-Class, premium gadgets, and other prizes have found their owners. FBS and its clients celebrated the trading community successfully, and here are...

at 05:00
Global energy and commodity price reporting agency Argus has launched two Carbon-Adjusted Price of Ammonia (CAPA) assessments that reflect the future impact of the Carbon Border Adjustment Mechanism (CBAM) on European ammonia prices....

News published on 4 february 2023 at 14:56 and distributed by: